Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN.
Miller Scientific Consulting, Inc, Asheville, NC.
J Arthroplasty. 2019 Feb;34(2):260-264. doi: 10.1016/j.arth.2018.09.085. Epub 2018 Oct 3.
The purpose of this study is to report healthcare payer costs of dual-mobility (DM) and large femoral head (LFH) constructs in revision total hip arthroplasties (THAs).
A Markov model was constructed to analyze costs of re-interventions incurred by Medicare and private payers over a 3-year time horizon in patients who underwent unilateral revision THA with DM (n = 126) or LFH (n = 176) implants. Model states and probabilities were derived from prospectively collected registry data. Medicare costs were estimated as the weighted-average national Medicare payment for revision THA. Private payer costs were estimated by using a multiplier of Medicare costs.
Over a 3-year period following revision THA, re-interventions were performed in 11 (9%) DM patients and 34 (19%) LFH patients, costing $263-$1898 in DM THAs and $1285-$3946 in LFH THAs for Medicare. When compared to LFH implants, DM constructs were less costly to Medicare and private payers, resulting in cost differentials of $1536 and $2611, respectively.
At mid-term follow-up, DM constructs utilized in revision THAs were associated with 11% lower absolute risk of re-intervention and payer savings of $1500-$2500 per case when compared to LFH constructs.
Economic and decision analysis, Level III.
本研究旨在报告在翻修全髋关节置换术中使用双动(DM)和大股骨头(LFH)假体的医疗保健支付者的成本。
构建了一个马尔可夫模型,以分析在接受单侧翻修全髋关节置换术的患者中,医保和私人支付者在 3 年时间内因再干预而产生的成本,这些患者使用 DM(n=126)或 LFH(n=176)假体。模型状态和概率源自前瞻性收集的注册数据。医保成本估计为医保支付的翻修全髋关节置换术的加权平均国家医保支付额。私人支付者成本使用医保成本的乘数来估计。
在翻修全髋关节置换术后的 3 年内,DM 组有 11 名(9%)患者和 LFH 组有 34 名(19%)患者需要进行再干预,DM 组的再干预费用为 263-1898 美元,而 LFH 组为 1285-3946 美元。与 LFH 假体相比,DM 假体对医保和私人支付者的成本更低,分别相差 1536 美元和 2611 美元。
在中期随访中,与 LFH 假体相比,用于翻修全髋关节置换术的 DM 假体的再干预绝对风险降低了 11%,每例可节省 1500-2500 美元的医保和私人支付者成本。
经济和决策分析,III 级。